In another phase III study (KEYNOTE-426), 432 advanced RCC patients were in the pembrolizumab–axitinib group and 429 patients were in sunitinib group, in which more than 50% patients in both groups had ≥1 of PD-L1 combined positive score [61]. Here, CD274 is linked to renal cell carcinoma.